Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia

被引：7
|
作者：
Wei, Hui [1 ,2 ,3 ,4 ]
Zhou, Chunlin [3 ,4 ]
Lin, Dong [3 ,4 ]
Liu, Bingcheng [3 ,4 ]
Li, Yan [3 ,4 ]
Zhao, Xingli [3 ,4 ]
Wei, Shuning [3 ,4 ]
Gong, Benfa [3 ,4 ]
Liu, Kaiqi [3 ,4 ]
Gong, Xiaoyuan [3 ,4 ]
Liu, Yuntao [3 ,4 ]
Zhang, Guangji [3 ,4 ]
Chen, Jiayuan [1 ]
Zhang, Junping [3 ,4 ]
Jin, Jingjing [3 ,4 ]
Qiu, Shaowei [3 ,4 ]
Gu, Runxia [3 ,4 ]
Wang, Ying [2 ,3 ,4 ]
Mi, Yingchan [1 ,2 ,3 ,4 ]
Wang, Jianxiang [1 ,2 ,3 ,4 ]
机构：
[1] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci, Inst Hematol, Natl Clin Res Ctr Blood Dis, Tianjin, Peoples R China
[3] Chinese Acad Med Sci, Inst Hematol, Leukemia Ctr, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 05期
基金：
中国国家自然科学基金;
关键词：
RANDOMIZED-TRIAL; ADULTS; DAUNORUBICIN; AML;
D O I：
10.3324/haematol.2020.267526
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1491 / 1495
页数：5
相关论文
共 50 条
  • [21] HIGH-DOSE MERCAPTOPURINE FOLLOWED BY INTERMEDIATE-DOSE CYTARABINE IN RELAPSED ACUTE-LEUKEMIA
    LOCKHART, S
    PLUNKETT, W
    JEHA, S
    RAMIREZ, I
    ZIPF, T
    CORK, A
    PINKEL, D
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) : 587 - 595
  • [22] Acute cerebellar syndrome following intermediate-dose cytarabine
    Yeshurun, M
    Dupuch, KM
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 846 - 846
  • [23] High-dose cytarabine induction for acute myeloid leukemia
    Shepherd, JD
    Barnett, MJ
    Phillips, GL
    BLOOD, 1996, 88 (02) : 754 - 754
  • [24] Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
    Stone, RM
    Berg, DT
    George, SL
    Dodge, RK
    Paciucci, PA
    Schulman, PP
    Lee, EJ
    Moore, JO
    Powell, BL
    Baer, MR
    Bloomfield, CD
    Schiffer, CA
    BLOOD, 2001, 98 (03) : 548 - 553
  • [25] EFFICACY OF ETOPOSIDE AND MITOXANTRONE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA REFRACTORY TO STANDARD INDUCTION THERAPY AND INTERMEDIATE-DOSE CYTARABINE WITH AMSIDINE
    DAENEN, S
    LOWENBERG, B
    SONNEVELD, P
    VANPUTTEN, WLJ
    VERHOEF, G
    VANVELDHOVEN, M
    HUIJGENS, PC
    LEUKEMIA, 1994, 8 (01) : 6 - 10
  • [26] Cytarabine Dose for Acute Myeloid Leukemia
    Lowenberg, Bob
    Pabst, Thomas
    Vellenga, Edo
    van Putten, Wim
    Schouten, Harry C.
    Graux, Carlos
    Ferrant, Augustin
    Sonneveld, Pieter
    Biemond, Bart J.
    Gratwohl, Alois
    de Greef, Georgine E.
    Verdonck, Leo F.
    Schaafsma, Martijn R.
    Gregor, Michael
    Theobald, Matthias
    Schanz, Urs
    Maertens, Johan
    Ossenkoppele, Gert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (11): : 1027 - 1036
  • [27] The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study
    Chen, Guofeng
    Yang, Jiaqi
    Cao, Fuliang
    Zhou, Wei
    Gong, Dan
    Liu, Liren
    Zhou, Dejun
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (16)
  • [28] Cytarabine Dose for Acute Myeloid Leukemia
    Medeiros, Bruno C.
    Othus, Megan
    Appelbaum, Frederick R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (22): : 2167 - 2168
  • [29] IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE CYTARABINE IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN CONTAINING HIGH DOSE CYTARABINE
    Maurillo, L.
    Buccisano, F.
    Spagnoli, A.
    Del Principe, M. I.
    Neri, B.
    Cefalo, M. G.
    De Angelis, G.
    Picardi, A.
    Ditto, C.
    Ammatuna, E.
    Del Poeta, G.
    Arcese, W.
    Lo Coco, F.
    Amadori, S.
    Venditti, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 25 - 26
  • [30] Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics
    Ji-hao Zhou
    Hai-qing Lin
    Qi Shen
    Li-na Hu
    Guo-qiang Li
    Xiong-fei Sun
    Xin-you Zhang
    Current Medical Science, 2018, 38 : 51 - 57
12345